MGTX Stock Analysis: Buy, Sell, or Hold?
MGTX - MeiraGTx Holdings plc Ordinary Shares
$9.09
0.43 (4.97%)
▲
5d:
+19.29%
30d:
+22.34%
90d:
+15.5%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
MGTX is down 4.1% this week, but smart money is accumulating calls. Top strike: $10 2026-04-17 with 785 OI. Call ratio: 100% View Scanner →
Strength: 7.0/10
Get Alerted When MGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: MGTX is 12.5% above fair value ($8.08). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: MGTX is 12.5% above fair value ($8.08). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: MGTX is currently trading at $9.09, which is considered extended relative to its 30-day fair value range of $7.20 to $8.08.
Technical Outlook: Technically, MGTX is in a downtrend. The price is approaching resistance at $9.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.25 (+188.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MGTX is in a downtrend. The price is approaching resistance at $9.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.25 (+188.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$7.20 -
$8.08
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BEARISH: Price significantly overextended (+12.5% above fair value)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BULLISH: Trading 188.8% below Wall St target ($26.25)
Fair Price Analysis
30-Day Fair Range
$7.20 -
$8.08
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$7.01
Resistance Level
$9.26
Current Trend
Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.22
Wall Street Target
$26.25
(+188.8%)
Revenue Growth (YoY)
252.3%
Profit Margin
-140.3%
Share & Embed Analysis
Last updated: April 02, 2026 6:01 AM ET
Data refreshes hourly during market hours. Next update: 7:01 AM
Data refreshes hourly during market hours. Next update: 7:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Giroux
SELL
24000 shares
2025-10-21
Alexandria Forbes
SELL
47500 shares
2025-10-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 63 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 62 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
